You are here
ARMAGEN TECHNOLOGIES, INC.
UEI: N/A
# of Employees: 9
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Bioengineering of a New Decoy Receptor Drug Delivery Technology
Amount: $111,999.00DESCRIPTION (provided by applicant): Decoy receptors are potential new pharmaceuticals to treat brain diseases, such as brain injury, spinal cord injury, stroke, or neurodegeneration. However, decoy r ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Iduronidase Replacement Therapy of the Brain in Hurler's Syndrome
Amount: $2,940,848.00DESCRIPTION (provided by applicant): Abstract There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment is ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
Iduronidase Replacement Therapy of the Brain in Hurler's Syndrome
Amount: $100,000.00DESCRIPTION (provided by applicant): There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment is enzyme re ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Bioengineering of a New Antibody Drug Delivery Technology
Amount: $149,050.00DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow disease, West ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Targeted Delivery of siRNA for Intravenous RNAi
Amount: $385,780.00DESCRIPTION (provided by applicant): RNA interference (RNAi) is a relatively new technology that enables the knockdown of expression of pathologic genes with short interfering RNAs (siRNAs). The limit ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Targeted Neurotrophin Drug Development in Parkinson's Disease
Amount: $100,000.00DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a severe degenerative condition of the brain that affects 1 million people in the U.S. PD is caused by the progressive neurodegeneratio ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Recombinant Enzyme Fusion Protein for Lysosomal Storage Disorders
Amount: $357,386.00DESCRIPTION (provided by applicant): Zhang, Yun Abstract There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of tr ...
SBIRPhase II2007Department of Health and Human Services National Institutes of Health -
Neuroprotection in Stroke Drug Development
Amount: $3,727,390.00DESCRIPTION (provided by applicant): Approximately 800,000 persons in the U.S. suffer an acute stroke each year. There presently is no neuroprotective agent that can be given to patients with acute s ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Stroke neuroprotection with a recombinant fusion protein
Amount: $749,152.00DESCRIPTION (provided by applicant): Approximately 800,000 persons in the U.S. suffer an acute stroke each year. There presently is no neuroprotective agent that can be given to patients with acute s ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Recombinant Enzyme Fusion Protein for Lysosomal Storage
Amount: $100,000.00DESCRIPTION (provided by applicant): There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment of the lysos ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health
